Literature DB >> 12490404

The N-linked glycan g15 within the V3 loop of the HIV-1 external glycoprotein gp120 affects coreceptor usage, cellular tropism, and neutralization.

Svenja Polzer1, Matthias T Dittmar, Herbert Schmitz, Michael Schreiber.   

Abstract

We have studied infectivity and neutralization of X4, R5, and R5X4 tropic HIV-1 mutants, which are lacking N-linked glycosylation sites for glycans g13, g14, g15, and g17 in the V3 loop region of gp120. X4-tropic NL4-3 mutants lacking combinations of g14/15 or g15/17 showed markedly higher infectivity in CXCR4-specific infection. The role of g15 in CCR5-specific infection was investigated using viruses with high (NL-918, R5-monotropic), medium (NL-991, R5-monotropic), and low (NL-952, R5X4-dualtropic) CCR5-specific infectivity. For NL-991, a reduction of infectivity on GHOST-CCR5 cells was observed for a mutant lacking g15. For NL-952 mutants all lacking g15, a complete loss of CCR5-specificity was observed and NL-952 was shifted from R5X4 to X4 tropism. For all mutants of NL4-3, NL-991, and NL-952, where the lack of g15 markedly influenced infectivity or coreceptor usage, neutralization was enhanced. In contrast, NL-918 mutants with or without g15 showed no difference in neutralization and no difference in GHOST-CCR5 infection rates. Thus, for viruses with a low or medium CCR5-specificity the role of g15 for changing CCR5-usage and sensitivity to neutralization was more significant than for viruses with high infection rates on GHOST-CCR5 cells. Our data demonstrate that V3 glycans play an important role in the usage of CXCR4 and CCR5. The lack of g15 was relevant for a more efficient use of CXCR4, whereas interaction with CCR5 was facilitated in the presence of g15. This study also demonstrates that glycan g15 is involved in blocking of neutralizing antibodies and shifting HIV tropism from R5X4 to X4.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12490404     DOI: 10.1006/viro.2002.1760

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  34 in total

1.  Potent intratype neutralizing activity distinguishes human immunodeficiency virus type 2 (HIV-2) from HIV-1.

Authors:  Gülsen Ozkaya Sahin; Birgitta Holmgren; Zacarias da Silva; Jens Nielsen; Salma Nowroozalizadeh; Joakim Esbjörnsson; Fredrik Månsson; Sören Andersson; Hans Norrgren; Peter Aaby; Marianne Jansson; Eva Maria Fenyö
Journal:  J Virol       Date:  2011-11-09       Impact factor: 5.103

2.  Characterization of glycopeptides from HIV-I(SF2) gp120 by liquid chromatography mass spectrometry.

Authors:  Jenny M Cutalo; Leesa J Deterding; Kenneth B Tomer
Journal:  J Am Soc Mass Spectrom       Date:  2004-11       Impact factor: 3.109

3.  Anti-human immunodeficiency virus type 1 (HIV-1) antibodies 2F5 and 4E10 require surprisingly few crucial residues in the membrane-proximal external region of glycoprotein gp41 to neutralize HIV-1.

Authors:  Michael B Zwick; Richard Jensen; Sarah Church; Meng Wang; Gabriela Stiegler; Renate Kunert; Hermann Katinger; Dennis R Burton
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

4.  Characterization of structural features and diversity of variable-region determinants of related quaternary epitopes recognized by human and rhesus macaque monoclonal antibodies possessing unusually potent neutralizing activities.

Authors:  Chavdar Krachmarov; Zhong Lai; William J Honnen; Aidy Salomon; Miroslaw K Gorny; Susan Zolla-Pazner; James Robinson; Abraham Pinter
Journal:  J Virol       Date:  2011-08-10       Impact factor: 5.103

5.  Development of a novel codon-specific polymerase chain reaction for the detection of CXCR4-utilizing HIV type 1 subtype B.

Authors:  Sherry McLaughlin; Luke C Swenson; Shengbo Hu; Paul Hughes; P Richard Harrigan; Robert W Coombs; Lisa M Frenkel
Journal:  AIDS Res Hum Retroviruses       Date:  2013-03-06       Impact factor: 2.205

6.  Emergence of CXCR4-using human immunodeficiency virus type 1 (HIV-1) variants in a minority of HIV-1-infected patients following treatment with the CCR5 antagonist maraviroc is from a pretreatment CXCR4-using virus reservoir.

Authors:  Mike Westby; Marilyn Lewis; Jeannette Whitcomb; Mike Youle; Anton L Pozniak; Ian T James; Tim M Jenkins; Manos Perros; Elna van der Ryst
Journal:  J Virol       Date:  2006-05       Impact factor: 5.103

7.  Distinct molecular pathways to X4 tropism for a V3-truncated human immunodeficiency virus type 1 lead to differential coreceptor interactions and sensitivity to a CXCR4 antagonist.

Authors:  Gregory Q Del Prete; George J Leslie; Beth Haggarty; Andrea P O Jordan; Josephine Romano; James A Hoxie
Journal:  J Virol       Date:  2010-06-23       Impact factor: 5.103

8.  Genotypic prediction of HIV-1 CRF01-AE tropism.

Authors:  Stéphanie Raymond; Pierre Delobel; Sylvie Rogez; Stéphanie Encinas; Patrick Bruel; Christophe Pasquier; Karine Sandres-Sauné; Bruno Marchou; Patrice Massip; Jacques Izopet
Journal:  J Clin Microbiol       Date:  2012-12-05       Impact factor: 5.948

9.  Glycosylation patterns of HIV-1 gp120 depend on the type of expressing cells and affect antibody recognition.

Authors:  Milan Raska; Kazuo Takahashi; Lydie Czernekova; Katerina Zachova; Stacy Hall; Zina Moldoveanu; Matt C Elliott; Landon Wilson; Rhubell Brown; Dagmar Jancova; Stephen Barnes; Jana Vrbkova; Milan Tomana; Phillip D Smith; Jiri Mestecky; Matthew B Renfrow; Jan Novak
Journal:  J Biol Chem       Date:  2010-05-03       Impact factor: 5.157

10.  Neutralization of X4- and R5-tropic HIV-1 NL4-3 variants by HOCl-modified serum albumins.

Authors:  Svenja Polzer; Melanie van Yperen; Martin Kirst; Birco Schwalbe; Heiner Schaal; Michael Schreiber
Journal:  BMC Res Notes       Date:  2010-06-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.